Modern Slavery Act 2015 – Transparency in Supply Chains Statement

for the year ended 31 December 2019

This statement is made pursuant to Part 6, Section 54 of the Modern Slavery Act 2015 (Transparency in Supply Chains) and applies to the following legal entities:

Abbott Laboratories Limited
Abbott Diabetes Care Limited
Abbott Medical U.K. Limited
Abbott Healthcare Products Ltd

(Collectively, “Abbott”)

Our Structure and Business

Abbott is a global healthcare company that conducts innovative research and manufacturers products for human health through every life stage. Abbott is a subsidiary of Abbott Laboratories and is headquartered in Chicago, USA.

Abbott is committed to safe and fair working conditions and this extends to the partners in our supply chain. Abbott’s understanding of slavery and human trafficking is based on the definitions set out in the Modern Slavery Act 2015 and is guided by the UN Universal Declaration of Human Rights and the conventions of the International Labour Organisation (ILO), in particular relating to forced or compulsory labour.

Policies and Training

Abbott employees, contract workers and agents are obliged to comply with Abbott’s Code of Business Conduct, which incorporates standards prohibiting slavery and human trafficking or engaging in illegal behaviour, by carrying out training on an annual basis. Abbott’s Code of Business Conduct can be found here: http://www.abbott.com/investors/governance/code-of-business-conduct.html.

Abbott provides training to its employees and management who have direct responsibility for supply chain management particularly with respect to mitigating risks within the supply chains of products. On an annual basis, Abbott employees involved in the purchasing function or who are in the position to influence a purchasing decision are required to review Abbott’s Supplier Guidelines, including in respect of ethical practices.

All Abbott suppliers are expected to follow the Abbott Supplier Guidelines, which document our principles, guidelines and expectations in areas including ethical behaviour, business integrity and fair competition; privacy, labour rights and worker protection; animal welfare, environmental stewardship; and health and safety practices. Our Guidelines, published in multiple languages, state that suppliers are prohibited from using forced, bonded or indentured labour, involuntary prison labour or human trafficking. Abbott’s Supplier Guidelines can be found here: http://www.abbott.com/partners/suppliers.html.

Due Diligence
Abbott’s Supplier Guidelines define the minimum standards that our suppliers and their suppliers must maintain when conducting business with our company. These include standards concerning ethical behaviour and anticorruption, business integrity and fair competition, human rights, privacy, labour rights and worker protection, animal welfare, environmental stewardship, conflict minerals and health and safety practices. Our Supplier Guidelines are published in multiple languages and are available on our website. Suppliers are responsible for confirming their compliance and providing relevant training.

When selecting suppliers, we consider environmental, social and governance factors, in addition to business capabilities and capacities, financial health and strategic alignment with Abbott’s vision. We use supplier classification models to identify critical suppliers, so we can form strategic partnerships with them to help manage risk. Our Approved Suppliers List categorises all Abbott suppliers as either high (critical), medium or low risk. Our critical suppliers include those supplying materials, components and services that can influence the safety and performance of our products, as well as those that are the only approved source of materials, components and services. Our assessment of risk and criticality also takes into account supply chain transparency and complexity, supplier certification, proximity to the patient and the potential for economically motivated adulteration.

We monitor supplier compliance with the basic principles outlined in our Supplier Guidelines, and we engage with critical and strategic suppliers that represent our greatest social sustainability risks and opportunities. As part of this process, we annually assess the performance of suppliers representing a high sustainability risk to ensure they meet our quality and social requirements. We have sustainability engagement programs for the sourcing categories with the highest levels of sustainability risk, and we engage with suppliers to help address the issues we identify. We use intelligence from our risk management tool to prioritise which suppliers we survey and audit. We have developed specific supplier audit programs for suppliers of chemicals of environmental concern and active pharmaceutical ingredients, as well as for waste vendors.

Abbott’s Supply Chain Council and Business Continuity group use a real-time risk intelligence and supplier mapping tool to track the geopolitical, security, sustainability, environmental and infrastructure risks that could affect Abbott’s supply chain.

Abbott’s Supplier Social Responsibility (SSR) program includes surveying and auditing critical suppliers to confirm adherence to our Supplier Guidelines. Abbott also conducted site audits at 30 suppliers that we identified as being high risk for sustainability issues. These audits utilised Workplace Conditions Assessment standards. In 65 per cent of cases, the audits were acceptable, with minor observations. We worked with the remaining suppliers to address the needs that the audits identified. In cases of major and zero-tolerance findings, we required our suppliers to implement corrective and preventive action plans, which had to be submitted in documented form within 30 days of the audit results being received by the supplier. In total, we have audited 8 per cent of our Tier 1 suppliers over the past three years.


Accountability

Adhering to our Code of Business Conduct is a condition of continued employment with Abbott. We investigate all reports of potential violations of our code, policies or procedures, and take appropriate corrective action. Any Abbott employee who violates our Code, or any policy or procedure is subject to appropriate disciplinary action.
Abbott employees and suppliers are expected to report violations or possible violations of the Supplier Guidelines to Abbott Purchasing or to the Abbott Office of Ethics and Compliance.

Abbott will promptly investigate reported violations of the Abbott Supplier Guidelines and expects employees and suppliers to cooperate in the investigation. If corrective action is required, Abbott will outline steps to address the issue.

**Governance**

Abbott offers several channels where questions can be asked and concerns can be raised, including via our “Speak Up” programme. Our Ethics and Compliance Helpline is multilingual and available globally 24/7 where there are concerns of a potential violation of Abbott's values and standards of conduct.

Abbott's position on human rights is reinforced in our Code of Conduct and employment, ethics and procurement policies.

This statement is made pursuant to section 54(1) of the Modern Slavery Act 2015 and constitutes Abbott's slavery and human trafficking statement for the financial year ending 31 December 2019. This statement was approved by the board on 24 June 2020.

Neil Harris  
Director  
Abbott Laboratories Limited  
Date: 29th June 2020

Christopher Graham Bass  
Director  
Abbott Diabetes Care Limited  
Date:

Kevan Gogay  
Director  
Abbott Medical U.K. Limited  
Date:

Neil Harris  
Director  
Abbott Healthcare Products Ltd  
Date: 29th June 2020

ADC-24269 (v1.0) 06.20
Abbott employees and suppliers are expected to report violations or possible violations of the Supplier Guidelines to Abbott Purchasing or to the Abbott Office of Ethics and Compliance.

Abbott will promptly investigate reported violations of the Abbott Supplier Guidelines and expects employees and suppliers to cooperate in the investigation. If corrective action is required, Abbott will outline steps to address the issue.

**Governance**

Abbott offers several channels where questions can be asked and concerns can be raised, including via our “Speak Up” programme. Our Ethics and Compliance Helpline is multilingual and available globally 24/7 where there are concerns of a potential violation of Abbott’s values and standards of conduct.

Abbott’s position on human rights is reinforced in our Code of Conduct and employment, ethics and procurement policies.

This statement is made pursuant to section 54(1) of the Modern Slavery Act 2015 and constitutes Abbott’s slavery and human trafficking statement for the financial year ending 31 December 2019. This statement was approved by the board on 24 June 2020.

Neil Harris  
Director  
Abbott Laboratories Limited  
Date:

Christopher Graham Bass  
Director  
Abbott Diabetes Care Limited  
Date: 25 Jun 20

Kevan Gogay  
Director  
Abbott Medical U.K. Limited  
Date:

Neil Harris  
Director  
Abbott Healthcare Products Ltd  
Date:

ADC-24269 (v1.0) 06.20
Abbott employees and suppliers are expected to report violations or possible violations of the Supplier Guidelines to Abbott Purchasing or to the Abbott Office of Ethics and Compliance.

Abbott will promptly investigate reported violations of the Abbott Supplier Guidelines and expects employees and suppliers to cooperate in the investigation. If corrective action is required, Abbott will outline steps to address the issue.

**Governance**

Abbott offers several channels where questions can be asked and concerns can be raised, including via our “Speak Up” programme. Our Ethics and Compliance Helpline is multilingual and available globally 24/7 where there are concerns of a potential violation of Abbott’s values and standards of conduct.

Abbott’s position on human rights is reinforced in our Code of Conduct and employment, ethics and procurement policies.

This statement is made pursuant to section 54(1) of the Modern Slavery Act 2015 and constitutes Abbott’s slavery and human trafficking statement for the financial year ending 31 December 2019. This statement was approved by the board on 24 June 2020.

Neil Harris  
Director  
Abbott Laboratories Limited  
Date:

Christopher Graham Bass  
Director  
Abbott Diabetes Care Limited  
Date:

Kevan Gogay  
Director  
Abbott Medical U.K. Limited  
Date: 25 June 2020

Neil Harris  
Director  
Abbott Healthcare Products Ltd  
Date:

ADC-24269 (v1.0) 06.20